SCYNEXIS (NASDAQ:SCYX) and Amarin (NASDAQ:AMRN) Critical Contrast

Amarin (NASDAQ:AMRN) and SCYNEXIS (NASDAQ:SCYX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, institutional ownership, profitability, earnings and risk.

Profitability

This table compares Amarin and SCYNEXIS’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Amarin	-14.56%	-0.20%	-0.14%
SCYNEXIS	-41.79%	-44.15%	-32.61%

Institutional and Insider Ownership

22.3% of Amarin shares are owned by institutional investors. Comparatively, 54.4% of SCYNEXIS shares are owned by institutional investors. 4.2% of Amarin shares are owned by insiders. Comparatively, 4.1% of SCYNEXIS shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Amarin and SCYNEXIS”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amarin	$186.23 million	1.50	-$38.80 million	($0.99)	-13.33
SCYNEXIS	$20.60 million	2.12	-$8.61 million	($2.09)	-2.10

SCYNEXIS has lower revenue, but higher earnings than Amarin. Amarin is trading at a lower price-to-earnings ratio than SCYNEXIS, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Amarin has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500. Comparatively, SCYNEXIS has a beta of 1.11, suggesting that its share price is 11% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Amarin and SCYNEXIS, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amarin	2	1	0	0	1.33
SCYNEXIS	1	0	2	0	2.33

Amarin presently has a consensus price target of $13.00, suggesting a potential downside of 1.52%. SCYNEXIS has a consensus price target of $33.00, suggesting a potential upside of 651.71%. Given SCYNEXIS’s stronger consensus rating and higher probable upside, analysts plainly believe SCYNEXIS is more favorable than Amarin.

Summary

SCYNEXIS beats Amarin on 8 of the 14 factors compared between the two stocks.

About Amarin

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

About SCYNEXIS

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.